Physician profile
Licheng Lee
NPI 1881890457
$4,936.47
in general payments reported to CMS, 2019-2025
30 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,675 · 2020: $388 · 2021: $154 · 2022: $1,402 · 2023: $827 · 2024: $362 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $948.01 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $652.86 | 2019-2025 | Lifevest |
| Amgen INC. | $538.47 | 2019-2024 | Repatha |
| Pfizer INC. | $312.44 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $288.46 | 2019-2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $276.82 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $254.39 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $247.06 | 2019-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $189.07 | 2019-2023 | |
| Boston Scientific Corporation | $180.59 | 2021-2023 | Watchman Access System |
| Astellas Pharma US INC | $175.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $121.20 | 2019-2023 | Farxiga |
| Braemar Manufacturing, LLC | $119.66 | 2019 | |
| Amarin Pharma, INC. | $95.46 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.62 | 2019-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $56.74 | 2020 | |
| Osprey Medical INC | $45.00 | 2019 | |
| Merck Sharp & Dohme LLC | $43.51 | 2021-2025 | Verquvo |
| Baxter Healthcare | $43.00 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lundbeck LLC | $42.15 | 2019 | |
| Gilead Sciences, INC. | $35.61 | 2019 | |
| Novo Nordisk INC | $33.42 | 2019-2024 | Wegovy |
| Lantheus Medical Imaging, INC. | $32.30 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.38 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $21.36 | 2019 | |
| Esperion Therapeutics, INC. | $19.59 | 2024 | Nexletol |
| Irhythm Technologies, INC. | $18.16 | 2023 | Zio Xt Patch |
| United Therapeutics Corporation | $18.15 | 2020 | |
| Portola Pharmaceuticals, LLC | $15.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Licheng Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.